15% TOPICAL RESORCINOL FOR HURLEY I-II HIDRADENITIS SUPPURATIVA.
NCT ID: NCT04099212
Last Updated: 2020-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
40 participants
OBSERVATIONAL
2019-05-15
2020-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fractional CO2 Laser Fenestration and Steroid Delivery in HS Lesions
NCT05580029
Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
NCT02805595
LAS41005 in Hyperkeratotic Actinic Keratosis
NCT01358851
Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa
NCT03203122
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
NCT05997277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases
Patients with HS I-II in monotherapy treatment of topical resorcinol 15%
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with HS Hurley I-II degree.
* Patients that have at least 1 or more swollen up nodules and/or abscess.
* Availability of affected region control ultrasound prior to resorcine treatment beginning.
Exclusion Criteria
* Number of draining fistula above 20.
* Patients in active treatment with immunomodulators.
* Patients in active treatment with antibiotics.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Moreno Ramírez
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Virgen Macarena
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Virgen Macarena
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
David Moreno Ramírez
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIS-RES-2018-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.